July 15, 2016
Leukemia Drug Could Have actually Rewards for Parkinson’s Disease
HealthDay News — Nilotinib, a drug utilized to handle leukemia, has actually revealed very first indications of guarantee for advanced cases of Parkinson’s disease, according to a study published in the Journal of Parkinson’s Disease.
Charbel Moussa, MD, PhD, assistant professor of neurology at the Georgetown University Medical Focus in Washington, D.C., and colleagues owned 12 patients along with either Parkinson’s disease dementia or dementia along with Lewy physiques take reduced doses of nilotinib daily for six months.
One patient owned to withdraw after 1 month as a result of heart complications, yet the drug was well tolerated in the remaining patients, Dr Moussa told HealthDay. The researchers discovered that nilotinib was detectable in the cerebrospinal fluid (CSF) and appeared to captivate the target Abl. Patients frequently showed some improvement in the 2 bodily symptoms and cognitive difficulties.
“We likewise obtained preliminary evidence of modifications in dopamine metabolic process in the CSF complying with procedure along with nilotinib. However, the participants did not constitute a homogenous cohort, and there were huge baseline differences in dopamine metabolite levels, making a definitive interpretation of these outcomes difficult,” the authors wrote. “Taken together, the data advise that it is warranted to relocate forward along with clinical trials to identify an right therapeutic dose and evaluate nilotinib effects in larger, randomized, double-blinded, placebo-controlled trials.”
Dr Moussa is listed as an inventor when it come to a Georgetown University intellectual property patent application to usage nilotinib for the procedure of neurodegenerative diseases.
Reference
Loading links….
